Novartis Vaccines, the second largest supplier of influenza vaccines in the US, plans to produce approximately 40 million doses of its Fluvirin vaccine for distribution in the US during the upcoming 2007/08 influenza season. This represents a 30% increase in supply compared to the previous influenza season.
Based on accelerated production plans, approximately half of these doses are planned for delivery by the end of September, with all doses expected to be delivered by the end of October. The exact timing of deliveries will depend on the release of doses by the US Food and Drug Administration.
Influenza vaccines are updated each year to address changes in viruses. Fluvirin contains three influenza virus strains identified in the annual public health expert assessment for the 2007-2008 season in the US.
Follow us on
